Home LiteratureArticle Details
PMID: 20798208 Published · ppublish English Journal Article Multicenter Study

Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy.

Cancer prevention research (Philadelphia, Pa.) ·Vol. 3 ·No. 9 ·2010-09-00 ·Pages 1093-103

Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, Goodman S, Sidransky D, Bermudez F, Jean-Charles G, McCaffrey T, Padhya T, Phelan J, Spivakovsky S, Bowne HY, Goldberg JD, Rolnitzky L, Robbins M, Kerr AR, Sirois D, Califano JA

Abstract

Endothelin receptor type B (EDNRB) and kinesin family member 1A (KIF1A) are candidate tumor suppressor genes that are inactivated in cancers. In this study, we evaluated the promoter hypermethylation of EDNRB and KIF1A and their potential use for risk classification in prospectively collected salivary rinses from patients with premalignant/malignant oral cavity lesions. Quantitative methylation-specific PCR was performed to analyze the methylation status of EDNRB and KIF1A in salivary rinses of 191 patients. We proceeded to determine the association of methylation status with histologic diagnosis and estimate classification accuracy. On univariate analysis, diagnosis of dysplasia/cancer was associated with age and KIF1A or EDNRB methylation. Methylation of EDNRB highly correlated with that of KIF1A (P < 0.0001). On multivariable modeling, histologic diagnosis was independently associated with EDNRB (P = 0.0003) or KIF1A (P = 0.027) methylation. A subset of patients analyzed (n = 161) without prior biopsy-proven malignancy received clinical risk classification based on examination. On univariate analysis, EDNRB and risk classification were associated with diagnosis of dysplasia/cancer and remained significant on multivariate analysis (EDNRB: P = 0.047, risk classification: P = 0.008). Clinical risk classification identified dysplasia/cancer with a sensitivity of 71% and a specificity of 58%. The sensitivity of clinical risk classification combined with EDNRB methylation improved to 75%. EDNRB methylation in salivary rinses was independently associated with histologic diagnosis of premalignancy and malignancy and may have potential in classifying patients at risk for oral premalignant and malignant lesions in settings without access to a skilled dental practitioner. This may also potentially identify patients with premalignant and malignant lesions that do not meet the criteria for high clinical risk based on skilled dental examination.

MeSH Terms
Adolescent Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/genetics,metabolism,pathology DNA Methylation/genetics Female Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease/genetics Humans Kinesins/genetics,metabolism Male Middle Aged Mouth/metabolism,pathology Mouth Neoplasms/genetics,metabolism,pathology Precancerous Conditions/genetics,metabolism,pathology Promoter Regions, Genetic Receptor, Endothelin B/genetics,metabolism Risk Factors Saliva/metabolism Young Adult
Chemicals
KIF1A protein, human Receptor, Endothelin B Kinesins
Authors & Affiliations
20 authors, click to expand affiliations / ORCID
Pattani Kavita Malhotra
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, 601 North Caroline Street, 6th Floor, Baltimore, MD 21287-0910, USA.
Zhang Zhe
Demokan Semra
Glazer Chad
Loyo Myriam
Goodman Steven
Sidransky David
Bermudez Francisco
Jean-Charles Germain
McCaffrey Thomas
Padhya Tapan
Phelan Joan
Spivakovsky Silvia
Bowne Helen Yoo
Goldberg Judith D
Rolnitzky Linda
Robbins Miriam
Kerr A Ross
Sirois David
Califano Joseph A
References (35)
35 references, click to expand
  1. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
    Urology. 2008 Jan;71(1):161-7 PMID: 18242387
  2. Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings.
    Oral Oncol. 2000 Nov;36(6):525-8 PMID: 11036246
  3. Oral cancer information in health education textbooks.
    J Cancer Educ. 2004 Spring;19(1):12-6 PMID: 15059751
  4. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.
    Clin Cancer Res. 2008 Jan 1;14(1):97-107 PMID: 18172258
  5. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
    Nat Med. 1995 Jul;1(7):686-92 PMID: 7585152
  6. Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan.
    Chin J Physiol. 2008 Feb 29;51(1):27-31 PMID: 18551992
  7. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers.
    Cancer Res. 2003 Aug 1;63(15):4620-5 PMID: 12907641
  8. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens.
    Prostate. 2004 Jun 15;60(1):25-31 PMID: 15129426
  9. Field change and oral cancer: new evidence for widespread carcinogenesis?
    Int J Oral Maxillofac Surg. 2002 Jun;31(3):262-6 PMID: 12190131
  10. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
    Cancer Res. 2004 Mar 15;64(6):1975-86 PMID: 15026333
  11. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
    Oncol Rep. 2006 Feb;15(2):507-11 PMID: 16391877
  12. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
    Cancer Res. 1996 Feb 15;56(4):722-7 PMID: 8631003
  13. Aberrant promoter methylation of EDNRB in lung cancer in Taiwan.
    Oncol Rep. 2006 Jan;15(1):167-72 PMID: 16328051
  14. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
    Eur Urol. 2007 Mar;51(3):665-74; discussion 674 PMID: 16956712
  15. Identification of aberrant promoter methylation of EDNRB gene in esophageal squamous cell carcinoma.
    Dis Esophagus. 2009;22(1):55-61 PMID: 18564167
  16. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
    J Urol. 2008 Feb;179(2):529-34; discussion 534-5 PMID: 18076941
  17. Prevention of head and neck cancer.
    Curr Oncol Rep. 2005 Mar;7(2):145-53 PMID: 15717949
  18. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.
    Int J Cancer. 2010 Nov 15;127(10):2351-9 PMID: 20162572
  19. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
    Cancer Res. 2001 Feb 1;61(3):939-42 PMID: 11221887
  20. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients.
    Clin Cancer Res. 2003 Apr;9(4):1370-5 PMID: 12684406
  21. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse.
    BMC Cancer. 2009 Oct 18;9:370 PMID: 19835631
  22. The cost-effectiveness of screening for oral cancer in primary care.
    Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv PMID: 16707071
  23. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 PMID: 8790415
  24. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma.
    Int J Cancer. 2002 Apr 10;98(5):651-5 PMID: 11920632
  25. Pharmacologic unmasking of epigenetically silenced genes in breast cancer.
    Clin Cancer Res. 2009 Feb 15;15(4):1184-91 PMID: 19228724
  26. Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. World Health Organization.
    Community Dent Oral Epidemiol. 1980 Feb;8(1):1-26 PMID: 6929240
  27. Promoter hypermethylation identifies progression risk in bladder cancer.
    Clin Cancer Res. 2007 Apr 1;13(7):2046-53 PMID: 17404085
  28. An assessment of oral cancer prevention curricula in U.S. medical schools.
    J Cancer Educ. 1998 Summer;13(2):90-5 PMID: 9659627
  29. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening.
    J Mol Diagn. 2001 Nov;3(4):164-70 PMID: 11687600
  30. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma.
    J Clin Pathol. 2003 Jan;56(1):52-5 PMID: 12499435
  31. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer.
    Int J Cancer. 2005 Nov 20;117(4):605-10 PMID: 15929076
  32. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma.
    Lancet Oncol. 2006 Jan;7(1):77-82 PMID: 16389187
  33. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer.
    Cancer Res. 1997 Jan 1;57(1):35-7 PMID: 8988036
  34. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
    Clin Cancer Res. 2004 Nov 15;10(22):7457-65 PMID: 15569975
  35. Critical evaluation of diagnostic aids for the detection of oral cancer.
    Oral Oncol. 2008 Jan;44(1):10-22 PMID: 17825602
Article Info
Journal
Cancer prevention research (Philadelphia, Pa.)
Abbr.
Cancer Prev Res (Phila)
ISSN
1940-6215
Published
2010-09-00
Epub
2010-00-26
Pages
1093-103
Language
English
Region
United States
NLM ID
101479409
PMCID
PMC2945229
Subset
IM
Grants
NIDCR NIH HHS · P50 DE019032-060001 · United States
NIDCR NIH HHS · P50 DE019032-070001 · United States
NCI NIH HHS · P50 CA096784-02 · United States
NCI NIH HHS · P50 CA096784 · United States
NIDCR NIH HHS · P50 DE019032-080001 · United States
NCI NIH HHS · U01 CA084986 · United States
NIDCR NIH HHS · P50 DE019032 · United States
NIDCR NIH HHS · U54 DE014257 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com